Edition:
United Kingdom

Evofem Biosciences Inc (EVFM.OQ)

EVFM.OQ on NASDAQ Stock Exchange Capital Market

2.19USD
17 Aug 2018
Change (% chg)

$0.02 (+0.92%)
Prev Close
$2.17
Open
$2.11
Day's High
$2.19
Day's Low
$2.11
Volume
2,382
Avg. Vol
14,271
52-wk High
$12.84
52-wk Low
$1.80

Chart for

About

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese... (more)

Overall

Beta: --
Market Cap(Mil.): $6.33
Shares Outstanding(Mil.): 13.83
Dividend: --
Yield (%): --

Financials

  EVFM.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.74 -- --
ROI: -80.14 15.07 14.61
ROE: -90.12 16.59 16.33

BRIEF-Evofem Biosciences Announces Pricing Of Public Offering Of Common Stock And Warrants

* EVOFEM BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

22 May 2018

BRIEF-Evofem Biosciences Files For Offering Up To 8 Million Shares Of Co's Stock

* EVOFEM BIOSCIENCES FILES FOR OFFERING UP TO 8 MILLION SHARES OF CO'S STOCK, COMMON WARRANTS TO BUY AGGREGATE OF 1.6 MILLION SHARES OF CO'S COMMON STOCK Source text: (https://bit.ly/2IIfAP7) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 May 2018

BRIEF-Evofem Biosciences Receives Fast Track Designation For Amphora For Prevention Of Chlamydia

* EVOFEM BIOSCIENCES RECEIVES FAST TRACK DESIGNATION FOR AMPHORA FOR PREVENTION OF CHLAMYDIA

21 Feb 2018

Earnings vs. Estimates